|
|
|
|
| LEADER |
01826nam a22003375i 4500 |
| 001 |
978-3-7643-7724-3 |
| 005 |
20191025061859.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2008 sz | s |||| 0|eng d |
| 020 |
|
|
|a 9783764377243
|
| 024 |
7 |
|
|a 10.1007/978-3-7643-7724-3
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Treatment of Psoriasis
|c edited by Jeffrey M. Weinberg.
|
| 250 |
|
|
|a 1st ed. 2008.
|
| 260 |
# |
# |
|a Basel :
|b Birkhäuser Basel :
|b Imprint: Birkhäuser,
|c 2008.
|
| 300 |
|
|
|a X, 183 p. 2 illus.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Milestones in Drug Therapy,
|
| 505 |
0 |
|
|a Introduction: History of psoriasis and psoriasis therapy -- The pathophysiology of psoriasis -- Psoriasis and psoriatic arthritis: a clinical review -- Topical therapy I: corticosteroids and vitamin D analogs -- Topical therapy II: retinoids, immunomodulators, and others -- Ultraviolet and laser therapy -- Traditional systemic therapy I: methotrexate and cyclosporine -- Traditional systemic therapy II: retinoids and others (hydroxyurea, thiopurine antimetabolites, mycophenlic acid, sulfasalazine) -- Biologic therapy for psoriasis: an overview of infliximab, etanercept, adalimumab, efalizumab, and alefacept -- Biologic and oral therapies in development for the treatment of psoriasis -- Quality of life issues in psoriasis.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Dermatology.
|
| 650 |
|
0 |
|a Immunology.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Dermatology.
|
| 650 |
2 |
4 |
|a Immunology.
|
| 700 |
1 |
|
|a Weinberg, Jeffrey M.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-7643-7724-3
|